HOME >> MEDICINE >> NEWS
Clinical trial of Etanercept for Wegener's disease shows no benefit

A Johns Hopkins-led study designed to evaluate the ability of etanercept to maintain disease remissions in a serious autoimmune disorder has failed to show any benefit. Etanercept, also called Enbrel, is a common treatment for rheumatoid arthritis and other types of joint inflammation.

"We had hoped that this approach to the treatment of Wegener's granulomatosis would be useful in preventing disease relapses," says John H. Stone, M.D., associate professor of medicine, director of the Johns Hopkins Vasculitis Center, and lead investigator of the study published in the Jan. 27, 2005, issue of the New England Journal of Medicine.

"The study results, however, demonstrate unequivocally that etanercept was not effective for this purpose. Because of the disease's propensity to flare following remission and the high risk of treatment complications associated with conventional therapies for Wegener's, we must continue to look for safe, effective ways of achieving and maintaining disease remissions," said Stone.

Wegener's granulomatosis is an uncommon disorder in which the body's immune system attacks its own blood vessels, damaging vital organs by limiting the flow of blood to lungs, kidneys, upper airways and other organs. The disease can affect people of any age and occurs in men and women with equal frequency.

Although current medications used to treat Wegener's halt the disease temporarily in most patients, 60 to 80 percent of patients eventually suffer from disease flares. The need to treat many patients repeatedly with medications such as glucocorticoids (prednisone), cyclophosphamide, and methotrexate leads to mounting morbidity from treatments. At the same time, each disease flare has the potential to cause irreversible damage. Wegener's granulomatosis frequently leads to kidney failure, hearing loss, damage to the respiratory tract, peripheral nerve injury, and other complications, according to Stone.

Etanercept, the f
'"/>

Contact: Trent Stockton
tstockt1@jhmi.edu
410-955-8665
Johns Hopkins Medical Institutions
26-Jan-2005


Page: 1 2 3

Related medicine news :

1. Clinical breast examination offers modest benefit to breast cancer screening program
2. Clinical trial participants fare no better, no worse than other patients
3. Clinical trial shows drug may offer a new option to prevent rejection of transplanted kidneys
4. National Academies news: Clinical research involving children
5. Clinical research key in advance to prospective health care
6. Clinical trial of new TB vaccine begins
7. Clinical trial of Alzheimers disease drug shows clear reductions in AD development
8. Clinical factors useful to identify heart failure patients with high risk of death
9. Panel: Clinical use of embryonic stem cells jeopardized by Bushs policy on federal funding
10. $7 million grant continues Asthma Clinical Research Network efforts
11. Clinical study of Penn State Hershey technology begins in South Africa

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... CHICAGO (PRWEB) , ... July 02, 2020 , ... ... technology intended for the treatment of autoimmune diseases. Its lead indication is ... for vitiligo at this time. , While vitiligo is equally prevalent ...
(Date:7/1/2020)... YORK (PRWEB) , ... July 01, 2020 , ... Dexur’s ... Colorado, showed that OrthoColorado Hospital , Porter Adventist Hospital , and ... 90-day episode for Hip & Knee Replacement. Dexur’s value analysis tracks a patient’s episode ...
(Date:6/28/2020)... ... June 26, 2020 , ... ... in the revision and redesignation of the ANSI/APSP/ICC-7 2013 American National Standard for ... Basins. PHTA is seeking member participation on the PHTA-7 Standard Writing Committee (SWC) ...
(Date:6/28/2020)... ... June 27, 2020 , ... The secret of surviving ... hundreds of rolls of toilet paper. Yet, it was the first product to disappear ... in theory. The more you have stockpiled, the less need to venture out, the ...
(Date:6/24/2020)... ... , ... Evolved Naturals, a new brand of CBD health and beauty products, ... newly launched website showcases a variety of health and beauty CBD products ... skincare & topical products . , Doug Gee, the CEO of Evolved ...
Breaking Medicine News(10 mins):
(Date:7/2/2020)... BOLINGBROOK, Ill. (PRWEB) , ... July 02, 2020 ... ... infographic: A Look at Medical Conditions that Chiropractors Treat. , “From migraines ... people with certain medical conditions,” according to the company. , Sourced from ...
(Date:7/1/2020)... ... July 01, 2020 , ... Lumeda ... today announced the formation of its Scientific Advisory Board with the appointment of ... and strategic advice to support company development and introduction of its PDT products ...
(Date:6/25/2020)... ... ... R3 Medical Training announced today it is now enrolling for its new ... course is August 6-7, 2020 in San Diego and the second is August 20-21, ... Stream option. , The two day agenda for each course is identical, covering a ...
Breaking Medicine Technology:
Cached News: